4Accepted Aug 27, 7:03 PM ET
REGENXBIO Director Gregory Ciongoli Buys Stock, Receives Awards
Accepted (ET)
7:03 PM
Aug 27, 2026
Filed
Aug 27, 2026
Documents
1
Size
11.8 KB
Summary
REGENXBIO Director Gregory Ciongoli Buys Stock, Receives Awards
What Happened
- Gregory Austin Ciongoli, a director of REGENXBIO, made open-market purchases and received equity awards. He purchased 49,196 shares on 2026-08-26 at a weighted average price of $9.14 ($449,706) and 53,407 shares on 2026-08-27 at a weighted average price of $9.36 ($499,676) — a total of 102,603 shares for about $949,382.
- On 2026-08-25 he was also granted equity awards: 15,432 shares reported as RSUs (time‑based restricted stock units) and 69,609 shares reported as a derivative award (an option grant), both reported at $0 cost in the filing.
Key Details
- Transaction dates and prices:
- 2026-08-26: Open‑market purchase, 49,196 shares, weighted avg $9.14 (range $8.67–$9.35). (Footnote F2)
- 2026-08-27: Open‑market purchase, 53,407 shares, weighted avg $9.36 (range $9.17–$9.4525). (Footnote F3)
- 2026-08-25: Award grants — 15,432 RSUs (F1) and 69,609 derivative award (option) (F4), both reported at $0.
- Shares owned after the transactions are not included in the provided excerpt of the Form 4.
- Notable footnotes:
- F1: The 15,432 RSUs vest 1/3 on each of Aug 25, 2027, 2028 and 2029, subject to continued service.
- F4: The option-like award vests 1/3 on Aug 25, 2027, then monthly in equal installments over the next 24 months, subject to service.
- F2/F3: Purchase prices are weighted averages from multiple trades; the filer can provide trade-by-trade detail on request.
- Filing timeliness: The report covers transactions on Aug 25–27 and was filed Aug 27, 2026 — within the typical two‑business‑day Form 4 deadline (i.e., timely).
Context
- The open‑market purchases are direct buys (purchase code P), which some investors consider a stronger signal than awards because they involve the insider deploying personal cash.
- The grants (code A) are time‑based awards (RSUs and a vesting option) that vest over future service periods and are not immediately marketable shares.
- All information above is factual from the Form 4; it does not imply motivation for the transactions.